| 
				健保碼及健保價 | 
		 
		
			| 
				See related Alkeran[威克瘤] information | 
		 
		
			| 
				  | 
		 
		
			| 
				製造商 | 
			
				GlaxoSmithKline | 
		 
		
			| 
				代理/經銷商 | 
			
				GlaxoSmithKline | 
		 
		
			| 
				成份 | 
			
				Melphalan | 
		 
		
			| 
				適應症 | 
			
				Listed in Dosage. | 
		 
		
			| 
				用量 | 
			
				Tab Multiple myeloma 0.15 mg/kg/day in divided doses for 4 days repeated at intervals of 6 weeks. Advanced ovarian adenocarcinoma 0.2 mg/kg/day for 5 days. Repeated 4-8 weekly or as soon as peripheral blood count has recovered. Polycythemia vera Remission induction: 6-10 mg daily for 5-7 days, then 2-4 mg daily until satisfactory disease control achieved. Maintenance: 2-6 mg once weekly. Inj Multiple myeloma 0.4 mg/kg repeated at appropriate intervals (eg. Once 4 weekly). Advanced ovarian adenocarcinoma 1 mg/kg at 4-week intervals. In combination with other cytotoxic drugs, 0.3-0.4 mg/kg at intervals of 4-6 weeks. Malignant melanoma Upper extremity perfusion: 0.6-1 mg/kg. Lower extremity perfusion: 0.8-1.5 mg/kg. Soft tissue sarcoma Upper extremity perfusion: 0.6-1 mg/kg. Lower extremity perfusion: 1-1.4 mg/kg. Advanced neuroblastoma 100-240 mg/m2 body surface area (sometimes divided equally over 3 consecutive days). | 
		 
		
			| 
				用法 | 
			
				Should be taken on an empty stomach (Take on an empty stomach 1 hr before or 2 hr after meals. Swallow whole, do not break/crush.). | 
		 
		
			| 
				美國食品藥物管理局之懷孕等級 | 
			
				
				Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). | 
		 
		
			| 
				禁忌 | 
			
				Pregnancy (1st trimester) & lactation. | 
		 
		
			| 
				注意事項 | 
			
				Monitor blood counts; patients who have recently received radiotherapy or other cytotoxic agents. Renal impairment. Ensure adequate contraceptive precautions. Should not administer into a peripheral vein. | 
		 
		
			| 
				不良反應 | 
			
				Bone marrow depression, thrombocytopenia, anemia; nausea, vomiting, diarrhea; stomatitis, alopecia, elevated blood urea. 
				View ADR Monitoring Website[參閱藥物不良反應監測表格] | 
		 
		
			| 
				交互作用 | 
			
				Avoid immunization with live vaccine. Nalidixic acid, cyclosporin. 
				View more drug interactions with Alkeran[威克瘤] | 
		 
	
 
 
	
		
			| 
				本商品之市售規格 | 
		 
		
			
				
					
						
							| 
								劑型 | 
							
								包裝 | 
							
								圖片 | 
						 
						
							| 
								Alkeran 錠劑  | 
							
								
									
										
											| 
												Alkeran 2 mg x 25's | 
											
												  | 
										 
									
								 
							 | 
						 
						
							| 
								Alkeran 乾粉注射劑  | 
							
								
							 | 
						 
					
				 
				 | 
		 
		
			
				
					
						
							
								
									
										
											| 
												Manufacturer: | 
											
												GlaxoSmithKline | 
										 
										
											| 
												Distributor: | 
											
												GlaxoSmithKline 
												  | 
										 
									
								 
							 | 
						 
					
				 
			 | 
		 
	
 
 |